Monoamines as Drug Targets in Chronic Pain: Focusing on Neuropathic Pain

Ficheros
Estadísticas
Métricas y Citas
Metadatos
Mostrar el registro completo del ítemFecha
2019-11Departamento/s
Neurociencias; PsicologíaFuente
Front. Neurosci. 13:1268Resumen
Monoamines are involved in regulating the endogenous pain system and indeed,
peripheral and central monoaminergic dysfunction has been demonstrated in certain
types of pain, particularly in neuropathic pain. Accordingly, drugs that modulate the
monaminergic system and that were originally designed to treat depression are now
considered to be first line treatments for certain types of neuropathic pain (e.g., serotonin
and noradrenaline (and also dopamine) reuptake inhibitors). The analgesia induced by
these drugs seems to be mediated by inhibiting the reuptake of these monoamines,
thereby reinforcing the descending inhibitory pain pathways. Hence, it is of particular
interest to study the monoaminergic mechanisms involved in the development and
maintenance of chronic pain. Other analgesic drugs may also be used in combination
with monoamines to facilitate descending pain inhibition (e.g., gabapentinoids and
opioids) and such combinations are often also used to alleviate certain types of
chronic pain. By contrast, while NSAIDs are thought to influence the monoaminergic
system, they just produce consistent analgesia in inflammatory pain. Thus, in this
review we will provide preclinical and clinical evidence of the role of monoamines in
the modulation of chronic pain, reviewing how this system is implicated in the analgesic
mechanism of action of antidepressants, gabapentinoids, atypical opioids, NSAIDs and
histaminergic drugs






